Literature DB >> 21310823

Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.

Marvin M van Luijn1, Willemijn van den Ancker, Martine E D Chamuleau, Adri Zevenbergen, Theresia M Westers, Gert J Ossenkoppele, S Marieke van Ham, Arjan A van de Loosdrecht.   

Abstract

Immune escape in cancer poses a substantial obstacle to successful cancer immunotherapy. Multiple defects in HLA class I antigen presentation exist in cancer that may contribute to immune escape, but less is known about roles for HLA class II antigen presentation. On class II(+) leukemic blasts, the presence of class II-associated invariant chain peptide (CLIP) is known to be correlated with poor survival in acute myeloid leukemia (AML). In this study, we evaluated the functional significance of CLIP expression on leukemic blasts of AML patients. CD4(+) T cells from patients were cocultured with autologous CLIP(-) and CLIP(+) primary leukemic blasts and analyzed for several functional parameters by flow cytometry. Increased HLA-DR and IFN-γ expression was observed for CD4(+) T cells stimulated with CLIP(-) leukemic blasts, in contrast to CLIP(+) leukemic blasts, which indicated an activation and polarization of the CD4(+) T cells toward T-helper 1 cells. In addition, CLIP(-) leukemic blasts induced greater outgrowth of effector memory CD4(+) T cells (with HLA-DR-restricted T-cell receptor Vβ repertoires) that were associated with better leukemia-specific reactivity than with CLIP(+) leukemic blasts. Our findings offer a clinical rationale to downmodulate CLIP on leukemic blasts as a strategy to degrade immune escape and improve leukemia-specific T-cell immunity in AML patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21310823     DOI: 10.1158/0008-5472.CAN-10-3689

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Authors:  Barbara Seliger; Matthias Kloor; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

2.  Isolation of human MHC class II-restricted T cell receptors from the autologous T-cell repertoire with potent anti-leukaemic reactivity.

Authors:  Luise U Weigand; Xiaoling Liang; Sabine Schmied; Sabine Mall; Richard Klar; Oliver J Stötzer; Christoph Salat; Katharina Götze; Josef Mautner; Christian Peschel; Angela M Krackhardt
Journal:  Immunology       Date:  2012-11       Impact factor: 7.397

3.  Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia.

Authors:  Marvin M van Luijn; Willemijn van den Ancker; S Marieke van Ham; Arjan A van de Loosdrecht
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

4.  Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia.

Authors:  Marvin M van Luijn; Theresia M Westers; Martine E D Chamuleau; S Marieke van Ham; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Am J Pathol       Date:  2011-09-09       Impact factor: 4.307

5.  Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.

Authors:  Eyal C Attar; Jeffrey L Johnson; Philip C Amrein; Gerard Lozanski; Martha Wadleigh; Daniel J DeAngelo; Jonathan E Kolitz; Bayard L Powell; Peter Voorhees; Eunice S Wang; William Blum; Richard M Stone; Guido Marcucci; Clara D Bloomfield; Barry Moser; Richard A Larson
Journal:  J Clin Oncol       Date:  2012-11-05       Impact factor: 44.544

6.  Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.

Authors:  Olesya Chornoguz; Alexei Gapeev; Michael C O'Neill; Suzanne Ostrand-Rosenberg
Journal:  Mol Cell Proteomics       Date:  2012-08-31       Impact factor: 5.911

7.  Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation.

Authors:  Marvin M van Luijn; Martine E D Chamuleau; Gert J Ossenkoppele; Arjan A van de Loosdrecht; S Marieke van Ham
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110

8.  Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.

Authors:  Jacques Thibodeau; Marie-Claude Bourgeois-Daigneault; Réjean Lapointe
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

9.  Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.

Authors:  Marvin M van Luijn; Arjan A van de Loosdrecht; Margit H Lampen; Peter A van Veelen; Adri Zevenbergen; Michel G D Kester; Arnoud H de Ru; Gert J Ossenkoppele; Thorbald van Hall; S Marieke van Ham
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

Review 10.  Dendritic cell-based immunotherapy for myeloid leukemias.

Authors:  Christian M Schürch; Carsten Riether; Adrian F Ochsenbein
Journal:  Front Immunol       Date:  2013-12-31       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.